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Abstract
Objective To assess the risk of venous thromboembolism from use of
combined oral contraceptives according to progestogen type and
oestrogen dose.
Design National historical registry based cohort study.
Setting Four registries in Denmark.
Participants Non-pregnant Danish women aged 15-49 with no history
of thrombotic disease and followed from January 2001 to December
2009.
Main outcome measures Relative and absolute risks of first time venous
thromboembolism.
Results Within 8 010 290 women years of observation, 4307 first ever
venous thromboembolic events were recorded and 4246 included, among
which 2847 (67%) events were confirmed as certain. Compared with
non-users of hormonal contraception, the relative risk of confirmed
venous thromboembolism in users of oral contraceptives containing
30-40 µg ethinylestradiol with levonorgestrel was 2.9 (95% confidence
interval 2.2 to 3.8), with desogestrel was 6.6 (5.6 to 7.8), with gestodene
was 6.2 (5.6 to 7.0), and with drospirenone was 6.4 (5.4 to 7.5). With
users of oral contraceptives with levonorgestrel as reference and after
adjusting for length of use, the rate ratio of confirmed venous
thromboembolism for users of oral contraceptives with desogestrel was
2.2 (1.7 to 3.0), with gestodene was 2.1 (1.6 to 2.8), and with
drospirenone was 2.1 (1.6 to 2.8). The risk of confirmed venous
thromboembolism was not increased with use of progestogen only pills
or hormone releasing intrauterine devices. If oral contraceptives with
desogestrel, gestodene, or drospirenone are anticipated to increase the
risk of venous thromboembolism sixfold and those with levonorgestrel
threefold, and the absolute risk of venous thromboembolism in current
users of the former group is on average 10 per 10 000 women years,
then 2000 women would need to shift from using oral contraceptives
with desogestrel, gestodene, or drospirenone to those with levonorgestrel
to prevent one event of venous thromboembolism in one year.
Conclusion After adjustment for length of use, users of oral
contraceptives with desogestrel, gestodene, or drospirenone were at
least at twice the risk of venous thromboembolism compared with users
of oral contraceptives with levonorgestrel.
Introduction
Theinfluenceofspecifictypesofcombinedoralcontraceptives
on the risk of thrombotic events remains the most important
safetyissuefortheseproducts.Severalstudieshaveinvestigated
the relation between combined oral contraceptives and venous
thromboembolism,
1-21 including newer large scale studies.
17-19
These new studies showed an increased risk of venous
thromboembolism in current users of combined oral
contraceptives and a decreasing risk by both time of use and
decreasing oestrogen dose.
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Research
RESEARCHResults on the significance of the type of progestogen differed.
Ten studies reported an increased relative risk of venous
thromboembolism among users of oral contraceptives with
desogestrel or gestodene compared with those containing
levonorgestrel,
1 2 4-7 9 13 17 18 a difference that was significant in
eight of the studies,
1 2 4-6 13 17 18 whereas a further three studies
found no difference.
8 14 19 In addition, four studies reported a
higher relative risk of venous thromboembolism among users
of combined oral contraceptives with drospirenone compared
with those containing levonorgestrel,
17 18 20 21 whereas two other
studies reported no difference.
14 19 Consequently, the European
Medicines Agency asked our study team to revisit the Danish
registrydataforadditionalanalyses,withafocusondifferences
in risk of venous thromboembolism between users of oral
contraceptiveswithdrospirenoneandthosewithlevonorgestrel
in the period after the launch of drospirenone in 2001.
We assessed the relative and absolute risk of first time venous
thromboembolismforusersoforalcontraceptiveswithdifferent
progestogens, different doses of oestrogen, and according to
certaintyofthediagnosisofvenousthromboembolism.Wealso
assessed the risk of venous thromboembolism in users of
progestogen only pills and hormone releasing intrauterine
devices.
Methods
WecarriedoutanationwidehistoricalcohortstudyofallDanish
women aged 15-49 during 1995-2009. The study focused on
the period after the launch of combined oral contraceptives
containingdrospirenonein2001.Informationonthe1.2million
womenofreproductiveageinDenmarkwascollectedfromfour
sources of data: Statistics of Denmark, the national registry of
patients, the national cause of death registry, and the national
registry of medicinal products.
Statistics of Denmark: identification of women
Statistics of Denmark keeps records of all Danish citizens. A
unique personal identification number is given to each citizen
atbirthorimmigration.Thisnumberisusedinpublicregistries,
enabling reliable linkage of data between registries. From
Statistics of Denmark we identified Danish women in the age
category 15-49 from 1 January 1995 to 31 December 2009. We
also obtained data on length of schooling, ongoing or finished
education, vital status, and emigration. Women were censored
at death or emigration.
National registry of patients: end points
The national registry of patients has collected discharge
diagnoses from all public and private hospitals in Denmark
since1977.From1994theregistryhasuseddiagnosesascoded
in the ICD-10 (international classification of diseases, 10th
revision). The web extra lists the codes used in this study.
To include first events only we excluded women with any type
of venous or arterial thrombotic event before the study period
(1977-2000). We also excluded women with malignant
gynaecological disease, cancer of abdominal organs or breast,
and lung or haematological cancer before the study period or
we censored them at the time of diagnosis if any of these
diseases occurred during the study period.
Surgery—the national registry of patients also records surgical
codes from public and private hospitals. We excluded women
at baseline who had undergone bilateral oophorectomy,
unilateral oophorectomy on two occasions, hysterectomy, or
sterilisation, or we censored them at the time of surgery.
Pregnancy—from the national patient registry we identified
pregnancyoutcomesandgestationalageattermination(seeweb
extra). We censored a woman’s experience during pregnancy,
as calculated from conception and three months after delivery
(one month for abortions and ectopic pregnancies), from study
follow-up.
Coagulation disturbances—we also excluded women with a
coagulationdisorderthefirsttimesuchadiagnosiswasrecorded
in the national patient registry, including Leiden factor V
heterozygote or homozygote, prothrombin 20210 heterozygote
orhomozygote,proteinCinsufficiency,proteinSinsufficiency,
and anti-thrombin III insufficiency.
National cause of death registry
As only those women admitted to hospitals would have been
recorded in the national registry of patients, we also checked
thenationalcauseofdeathregistryforlethaleventsfromvenous
thromboembolism(seewebextratable)duringthestudyperiod
(updated to 2008).
National registry of medicinal products: data
on contraceptive usage
Since1January1994thenationalregistryofmedicinalproducts
has collected information about filled prescriptions, including
oral contraceptives. From this database we obtained daily
updated information on redeemed prescriptions of oral
contraceptivesfrom1995to2009.Wecategorisedtheproducts
according to progestogen type, oestrogen dose, and length of
use. Oral contraceptives with levonorgestrel and 30-40 µg
ethinylestradiolweresubcategorisedasphasicpreparationswith
30-40 µg ethinylestradiol or combined pills with 30 µg
ethinylestradiol.
A stepwise analysis was undertaken, including successively
each of the following usage categories: starting use, defined as
useofcombinedoralcontraceptiveswithnohistoryofhormonal
contraception before the first prescription; new use, defined as
startinguseafterapauseofatleast12weeksforanyprescription
of a hormonal contraceptive; restarted use, defined as oral
contraceptive use after a pause of 4-11 weeks; and switched
use, defined as use of one preparation of oral contraceptive
followed by use of a different preparation, within a pause of
less than four weeks.
Duration of use
We estimated the duration of new use from the prescribed
defineddailydosescalculatedfromthedateofprescriptionuntil
the end date of defined daily doses of the last redeemed
prescription or date of a study event. The duration of restarted
use was defined as the period from the date of restart until the
end date of defined daily doses of the last filled prescription or
the date of a study event. Duration of switched use was
calculated as the sum of use before switch and current use on
thenewpreparation,untilenddateofdefineddailydosesofthe
last filled prescription or date of a study event. Thus the same
woman could have several episodes of new, restarted, and
switched use.
To account for use before the start of the study (left censoring
bias),weassessedtheuseoforalcontraceptivesbeforethestudy
periodbackto1995.Indoingthisweallocatedcontinuoususers
ofhormonalcontraceptivestotherelevantcategoryforduration
of use on 1 January 2001.
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RESEARCHRules for allocation of person time to usage
groups
We used four overall rules (see web extra for further details) to
allocate products to each usage group:
Rule 1—a woman’s time at risk for venous thromboembolism
was allocated to the oral contraceptive preparation prescribed
fromthedateitwasredeemeduntiltheenddatecalculatedfrom
defined daily doses. If no new prescription was redeemed by
four weeks after this end date, then we changed the woman’s
usagestatustoprevioususer.However,ifthewomangotanew
prescription for the same product within four weeks, we
considered it continuous current use.
Rule2—ifawomangotanewprescriptionforthesameproduct
beforetheenddateofthepreviousprescription,wesummarised
the prescribed defined daily doses as continuous current use.
Rule 3—if a woman cashed a new prescription for a different
product before the end date of the previous prescription, we
excluded the first four weeks after filling the new prescription
in either oral contraceptive category, because it would be
difficult to know which of the two products would account for
venous thromboembolism. After four weeks we categorised
such the woman as a switched user of the new preparation. In
this case we estimated the duration of use from the first
prescription of the previous preparation.
Rule 4—if a prescription ended and thereafter a woman
redeemedaprescriptionforaneworalcontraceptiveaftermore
than four weeks and less than 12 weeks, we estimated the
episodeofrestartedusefromthedatewhenthenewprescription
was filled. The gap was considered as previous use.
Confounding
Social class
We used length of schooling and level of education as proxies
for social class. Four strata were applied: women with
elementary school education only (9-10 years of schooling),
women with ongoing or completed high school education (2-3
years after elementary school), women with high school and
ongoingorendedmiddleeducation(3-4yearsafterhighschool),
and women with high school and ongoing or ended long
education(5-6yearsafterhighschool).Afifthcategoryincluded
womenlackinginformationoneducation,typicallytheyoungest.
Body mass index
The type of oral contraceptive could be related to body mass
index as a consequence of the secular increases in body mass
indexanduseofrecentlylaunchedcombinedoralcontraceptives
by time. We controlled for calendar year to deal with potential
long term confounding by body mass index. In addition we
carriedoutsubanalysesfortheperiods2001-5,2006-May2007,
and June 2007-9. We chose these periods because of new data
after 2005 and because of a “pill crisis” in Denmark in June
2007afterextensivemediaattentionononewomanwithvenous
thromboembolism who used oral contraceptives with
drospirenone.
Smoking
Data on smoking were not available. Smoking is a weak risk
factor for venous thromboembolism in young women.
13 We
have no reason to believe in preferential prescribing of specific
oralcontraceptivesamongsmokers.InDenmarkthecorrelation
between smoking and length of education is strong. Thus,
controlling for years of schooling and length of education may
havecapturedmostconfounding(ifany)influencedbysmoking.
Ovarian stimulation drugs
Women treated for infertility with ovarian stimulation drugs
(Anatomical Therapeutic Chemical classification G03G) are
anticipated to be at an increased risk for venous
thromboembolism.Thereforewecensoredthesewomenatfirst
such treatment.
Recent surgery
Fromthenationalregisterofpatientsweidentifiedwomenwith
venous thromboembolism who had undergone major surgery
in the four weeks before admission. Major surgery was defined
as a length of stay after surgery of more than one day, or
orthopaedic surgery on the legs. We carried out sensitivity
analyses with and without these women excluded.
Validity of the outcome diagnoses in the
national register of patients
All events of venous thromboembolism during 2001-9 were
cross checked with the national registry of medicinal products
for anticoagulation therapy (defined as therapy with vitamin K
antagonists or heparin). We defined women who were given
anticoagulation therapy for at least four weeks as having
confirmed venous thromboembolism. Thus we were able to
restrict analyses to confirmed events only.
Furthermore, we validated the hospital charts of 200 randomly
selected women with venous thromboembolism. Two
independent skilled clinicians evaluated each chart and
categorised each case as confirmed if two of three conditions
were fulfilled: clinical signs of venous thromboembolism;
diagnosticconfirmationbyultrasound,phlebography,computed
tomography, or scintigraphy (in case of pulmonary embolism);
and at least four weeks of anticoagulation therapy after the
diagnosis. The evaluation was done without knowledge of
registry data on usage of oral contraceptives.
Statistical analysis
Data were analysed by multiple Poisson regression in five year
age groups. We further stratified the estimates according to
length of current use into: less than three months, 3-12 months,
more than 12 months to four years, and more than four years.
We calculated absolute as well as relative risk estimates.
Non-users of all types of hormonal contraception (never users
plus former users) were used as the reference group for the
relative risk estimates. Rate ratios were also calculated for the
different product types. We adjusted the relative risk estimates
for age, calendar year, length of schooling and education, and
eventually for length of oral contraceptive use.
Sensitivity analyses were done for both different steps in
exposure line formation and according to different categories
of oral contraceptive use. We calculated three estimates of
exposure lines: raw exposure analyses, in which no gap filling
orextensionoffourweekswasrealised;gapcorrectedexposure
lines, in which gaps of less than four weeks were filled and (as
a consequence of filling out gaps) exposures were prolonged
with four weeks; and switch corrected exposure lines, in which
we excluded the first four weeks after switch.
Four successive analyses were carried out for the exposure
categories of starting oral contraceptives, adding new use,
restarted use, and, finally, switched use.
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RESEARCHResults
During1995to20091732254Danishwomenaged15-49were
identified, corresponding to 17 329 718 women years of
observation. The study period from January 2001 to December
2009 included 1 436 130 women and 9 954 925 observation
years. Among these women 455 421 (31.7%) had never used
hormonal contraception and 980 709 (68.3%) were ever users
of some kind of hormonal contraception.
Afterexclusionsandcensoringowingtopregnancy(n=403972
or 486 037 women years); ovarian stimulation (n=74 823 or
460 454 women years); previous cardiovascular disease
including venous thromboembolism (n=31 252 or 135 828
women years); cancer (n=21 080 or 135 828 women years);
coagulation disturbances (n=5122 or 19 258 women years);
hysterectomy, bilateral oophorectomy, or sterilisation (n=146
019 or 760 449 women years); censoring after three years of
usingahormonereleasingintrauterinedevice(n=48875or164
270 women years); and one month exclusions at switch of oral
contraceptive use (n=252 968 or 32 598 women years), 1 296
120womenwereincludedinthestatisticalanalysis,contributing
8 010 290 women years of observation, with 4307 first time
venous thromboembolic events recorded.
The venous thromboembolic events were distributed, with 82
(1.9%)womenhavingcerebralvenousthrombosis,2738(63.6%)
deep venous thrombosis only, 1130 (26.2%) pulmonary
embolism(withorwithoutdeepvenousthrombosis),55(1.3%)
portal thrombosis, 15 (0.4%) cava thrombosis, 4 (0.1%)
thrombosis of a kidney vein, and 283 (6.6%) unspecified deep
vein thrombosis.
Of the 4307 venous thromboembolic events, 61 occurred in
women using hormonal contraceptives with so little exposure
time and so few venous thromboembolic events that we did not
calculate estimates.
The adjusted relative risk increased 6.8-fold from the youngest
to the oldest women, and by 41% over the study period (5.1%
per year), and was reduced by 51% with increasing length of
education (table 1⇓).
Relative risk according to progestogen type
and oestrogen dose
Table 2⇓ shows the absolute and relative risks of venous
thromboembolism in current users of combined oral
contraceptiveswithdifferenttypesofprogestogensandvarying
doses of oestrogen. The incidence rate of venous
thromboembolisminnon-usersofcombinedoralcontraceptives
was 3.7 per 10 000 women years. Compared with non-users,
the relative risk of venous thromboembolism in current users
of oral contraceptives with levonorgestrel and 30 μg
ethinylestradiolwas2.19(95%confidenceinterval1.74to2.75)
and with levonorgestrel phasic 30-40 μg ethinylestradiol was
2.28 (1.85 to 2.83). The relative risk of venous
thromboembolism in current users of oral contraceptives with
30μgethinylestradiolcombinedwithdesogestrelwas4.21(3.63
to 4.87), with gestodene was 4.23 (3.87 to 4.63), and with
drospirenone was 4.47 (3.91 to 5.11). The corresponding
estimates for oral contraceptives with the same progestogens
but 20 μg ethinylestradiol were 3.26 (2.88 to 3.69), 3.50 (3.09
to 3.97), and 4.84 (3.19 to 7.33). Progestogen only products
conferred no increased risk of venous thromboembolism,
whether taken as low dose norethisterone pills, as desogestrel
only pills, or in the form of hormone releasing intrauterine
devices.
The relative risk of venous thromboembolism from using oral
contraceptiveswithnorethisterone,levonorgestrel,desogestrel,
orgestodenedecreasedwithdecreasingoestrogendose,whereas
no difference was apparent between oral contraceptives with
drospirenone and either 30 μg ethinylestradiol or 20 μg
ethinylestradiol. Oral contraceptives containing drospirenone
and 20 μg ethinylestradiol were launched in Denmark in 2006.
Relative risk by validity of diagnosis
The venous thromboembolic events were stratified into
confirmed (anticoagulation therapy recorded in the national
registry of medicinal products) and unconfirmed (table 3⇓). Of
the 4246 events diagnosed among non-users of hormonal
contraceptionoramongusersofproductsincludedinthisstudy,
2847 (67.1%) were confirmed and 1399 (32.9%) had no or less
than four weeks’ anticoagulation therapy recorded in the
registry. The relative risks of venous thromboembolism were
generally twofold to threefold higher in the confirmed group
than the unconfirmed group. Thus in the confirmed group the
relative risk of venous thrombolism with use of oral
contraceptives with levonorgestrel increased to around 3, and
for oral contraceptives with desogestrel, gestodene,
drospirenone, or cyproterone and 30 μg ethinylestradiol
increased to at least 6.
Progestogen only products had relative risk estimates below
unity compared with non-users in both the confirmed and the
unconfirmed groups.
The rate ratio between the estimates in the confirmed and
unconfirmed groups was highest for oral contraceptives with
desogestrel and lowest for those with norethisterone (table 3).
The proportion of confirmed events for specific oral
contraceptives varied from 64% to 84%, and ranged from 72%
to 78% for those with levonorgestrel, norgestimate, gestodene,
and drospirenone and from 76% to 84% for those with
desogestrel.
Table4⇓showstherateratioestimatesbetweendifferentproduct
types. In the confirmed group, oral contraceptives with
desogestrel,gestodene,ordrospirenoneconferredatleasttwice
the risk of venous thromboembolism compared with oral
contraceptives with levonorgestrel, and the rate ratio between
oralcontraceptiveswithdrospirenoneandthosewithdesogestrel
or gestodene was 1.01 (0.86 to 1.18). The corresponding rate
ratios in the unconfirmed group were generally lower. The
comparisonbetweenoralcontraceptiveswithdrospirenoneand
those with levonorgestrel was thus 1.78 (1.21 to 2.60), or 16%
lower than the 2.12 (1.68 to 2.66) in the confirmed group. The
rate ratio between these two product groups for all venous
thromboembolic events was 2.00 (1.64 to 2.43), not far off the
estimate in the confirmed group.
Relative risk adjusted for differences in length
of use
To account for differences in the distribution of lengths of use
betweenthegroups,analysesweredoneinwhichtherateratios
with oral contraceptives containing levonorgestrel and 30 µg
ethinylestradiol as reference were adjusted for differences in
length of use and restricted to confirmed events (table 5⇓). The
rate ratio estimates were slightly reduced for the newest
products, reflecting a relatively higher proportion of short term
users in these groups. The overall results, however, were
unchanged, and the rate ratio between oral contraceptives with
drospirenone compared with those containing levonorgestrel
was still 2.09 (1.55 to 2.82). Table 6⇓ displays detailed results
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progestogen types and oestrogen dose.
Sensitivity analyses
Relative risk through different steps in exposure
line formation
In preliminary analyses, the influence of different steps in the
exposure line formation was investigated. In the raw exposure
lines no gap filling or prolongation of exposure was realised.
The adjusted rate ratio between oral contraceptives with
drospirenone and 30 μg ethinylestradiol and those with
levonorgestrel and 30-40 μg ethinylestradiol was 2.2 (1.7 to
2.8),andbetweenoralcontraceptiveswith30μgethinylestradiol
and drospirenone versus oral contraceptives with 30 µg
ethinylestradiol and desogestrel or gestodene the rate ratio was
1.1 (0.9 to 1.3).
In the gap corrected dataset these rate ratio estimates were
unchanged, as they were in the dataset for switch corrected
exposure lines. For this reason the analyses were done with all
allocation rules applied (see web appendix 2).
Relative risk in different sub-periods
Another exploratory step in the analysis was to assess rate ratio
estimates in three sub-periods. A non-significant tendency was
for lower rate ratios for oral contraceptives with drospirenone
comparedwiththosecontaininglevonorgestrelinthelastperiod,
but for the period 2001-9 the adjusted rate ratio between oral
contraceptives with drospirenone and 30 μg ethinylestradiol
compared with those containing levonorgestrel and 30-40 μg
ethinylestradiol was 2.00 (1.64 to 2.43), and for the sub-period
2001-5was2.16(1.65to2.83).Similarresultswerefoundwhen
oral contraceptives with other progestogens were compared
with those containing levonorgestrel (see web extra appendix
3).Consequently,subsequentanalysesweredoneforthewhole
period 2001-9.
Results for different exposure categories
Sensitivity analyses were also done according to different user
categories,includingsuccessivelyfirststartersonly,thenstarters
and new users, then including restarters, and finally including
switchers. Starters had slightly higher rate ratios between users
of oral contraceptives with drospirenone compared with those
containing levonorgestrel of 2.69 (1.76 to 4.10) than estimates
including the other categories, where the same rate ratios were
between 1.96 (1.57 to 2.44) and 2.05 (1.56 to 2.70). See web
extra appendix 4 for details.
Different reference groups
A third methodological issue was the oestrogen component in
the levonorgestrel products used as reference. The rate ratio of
venous thromboembolism between users of oral contraceptives
with levonorgestrel and 30 μg ethinylestradiol and with
levonorgestrel and 30-40 μg ethinylestradiol including phasic
products did not differ significantly in any of the sub-periods.
About half of women years using oral contraceptives with
levonorgestrel contained 30 μg ethinylestradiol, the other half
phasicproducts30-40μgethinylestradiol.Fortheperiod2001-9,
therateratiobetweenoralcontraceptiveswithdrospirenoneand
30μgethinylestradiolandalllevonorgestrelproductswith30-40
μg ethinylestradiol was 2.00 (1.64 to 2.43) and with only
levonorgestrel and 30 μg ethinylestradiol was 2.04 (1.58 to
2.63). Accordingly, all users of oral contraceptives with
levonorgestrel and 30 μg or 30-40 μg ethinylestradiol were
chosen as reference group. For rate ratio comparisons with
specifically drospirenone, however, estimates with both 30 μg
ethinylestradiol and all levonorgestrel users were calculated.
Recent surgery
Among women with confirmed venous thromboembolism, 33
(1.2%)hadmajorsurgeryinthefourweeksbeforetheadmission
for venous thromboembolism. The results were similar with
and without exclusion of women with recent surgery. Thus the
rateratiobetweenoralcontraceptiveswithdrospirenoneand30
µg ethinylestradiol compared with those containing
levonorgestrelwas2.18(1.62to2.94)withtheseeventsincluded
and 2.13 (1.58 to 2.87) without.
Chart evaluation of venous thromboembolism
events
Of 200 evaluated hospital charts, 148 (74%) venous
thromboembolic events were confirmed and 52 unconfirmed.
Except for two women with distal limb thrombosis who were
not offered anticoagulation therapy, the remaining 146
confirmed events were in women who had received
anticoagulation therapy. However, two unconfirmed events
were in women who had received anticoagulation therapy; one
forarecentvenousthromboembolism,whichwasnotexcluded
because it was coded at the primary admission (before actual
admission) with a superficial venous thrombosis diagnosis and
therefore not excluded as previous venous thromboembolism.
The other woman was treated for connective tissue disease. All
200 evaluated patients coded as having venous
thromboembolism had clinical symptoms at admission.
Of the 200 validated events, 148 (74.0%) women had received
anticoagulation therapy according to the medical charts. Of
these, 133 (89.9%) were recorded in the national registry of
medicinal products as having had anticoagulation therapy,
suggesting that about 10% received treatment for free from the
hospitals, and therefore were not recorded in the registry.
Among the 52 women without information on anticoagulation
therapy in the medical charts, four (7.7%) were recorded in the
registry as having received anticoagulation therapy. This can
occurwhentreatmentstartsafterdischargefromthedepartment
to which the women were primarily admitted—that is, initiated
from a coagulation laboratory just after discharge from the
department. If these four events were added to the confirmed
events in the sample of 200 women, the confirmed proportion
increased to 152 of 200, or 76.0%.
Discussion
This study found that when compared with non-users of
hormonal contraception, current users of oral contraceptives
with levonorgestrel were at a threefold increased risk for
confirmed venous thrombosis and users of oral contraceptives
withdesogestrel,gestodene,drospirenone,orcyproteroneacetate
a sixfold to sevenfold increased risk. This would give a rate
ratio between the groups using oral contraceptives with
desogestrel, gestodene, drospirenone, or cyproterone and those
using oral contraceptives with levonorgestrel of at least 2.
Before interpreting the results of this analysis, the main
differences in study design and analysis between the present
and the primary publication
18 should be revisited. Potential
biases in our primary publication were dealt with as follows:
weeliminatedleftcensoringbiasbylettingthenewstudyperiod
begin in 2001, with full exposure history for the previous six
years; we defined length of use as duration of actual use rather
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durationofuse,insteadofthree,ensuringamoredetailedlength
of use allocation within the first year; we excluded the first
exposure month after a switch, because of uncertainty as to
which product group a woman should be allocated in case of
venousthromboembolisminthisperiod;analyseswerestratified
intoconfirmedandunconfirmedvenousthromboembolicevents;
andamoreeffectiveexclusionofpredisposedwomenincluding
women with coagulation disorders was effected.
Results according to progestogen type and
oestrogen dose
The addition of four more study years from 2006-9 and the
restrictionoftheanalysestotheperiodafter1January2001did
not change the overall results of our primary publication
covering 1995-2005. With the additional data we reconfirmed
andsubstantiatedadifferentialriskofvenousthromboembolism
between users of combined oral contraceptives with different
progestogens and (although to a less extent) with different
oestrogen doses.
According to the present analysis, with the same dose of
oestrogen, combined oral contraceptives containing the
progestogens desogestrel, gestodene, cyproterone, or
drospirenone confer about the same relative risk of venous
thromboembolism, a risk that is about twice that from use of
combined oral contraceptives with the same dose of oestrogen
and levonorgestrel. Phasic combined oral contraceptives with
levonorgestrelmayconferaslightlybutnotsignificantlyhigher
risk of venous thromboembolism than oral contraceptives with
levonorgestrel and 30 µg ethinylestradiol, which could be due
totheslightlyhighertotaldoseofoestrogenintheformergroup.
Consequently the relative risk estimates are slightly smaller
when the reference group was the whole group of oral
contraceptivescontaininglevonorgestrelthanifcomparedwith
only oral contraceptives with levonorgestrel and 30 μg
ethinylestradiol.
The oral contraceptives with desogestrel or gestodene and 20
μg ethinylestradiol implied a relative risk of venous
thromboembolismthatwere23%and17%lowerthanthesame
progestogenswith30μgethinylestradiol.Themissingtrendfor
oral contraceptives with drospirenone according to oestrogen
dosecouldbeaconsequenceoffewerevents(n=23)inthegroup
using 20 µg ethinylestradiol, more active pill per cycle for one
of the 20 µg products , or could also be influenced by the
introduction of these oral contraceptives in 2006, on the
assumption that attention to adverse effects is highest for new
products. However, the 70% confirmed venous
thromboembolism events in the new low dose drospirenone
group was close to the proportion of confirmed events for the
older oral contraceptives with drospirenone and 30 μg
ethinylestradiol (74%), which does not support differential
attention by women or their doctors.
Rate ratios and validity of diagnosis
More than two thirds of the included venous thromboembolic
events were confirmed by a record of anticoagulation therapy
inthenationalregistryofmedicinalproducts.Importantly,some
women have treatment for free (owing to local policies in some
hospitals when handing out these drugs) and consequently are
not recorded in the registry. According to our random analysis
ofmedicalcharts,anadditional10%arewomenwithrealevents
ofvenousthromboembolism,receivinganticoagulationtreatment
forfreefromthehospitals.Afurthersmallpercentageofwomen
start treatment after discharge, bringing the real proportion of
confirmed events up to 152 of 200, or 76%.
In a previous case-control study during 1994-8, we got
information from departments that 3.6% of cases were
unconfirmed.
13 In addition, 95 of 1094 (8.7%) women who
responded could not confirm their diagnosis, leaving what we
considered to be 87.7% of valid cases. The stricter validation
in the subsample in this study resulted in 76% with a valid
diagnosis. The difference of about 10% may be explained by
women who have clinical symptoms of venous
thromboembolism at admission that could not be confirmed by
radiographyorultrasonography.Suchwomencouldbetoldthat
they might have had venous thromboembolism that dissolved
spontaneouslyorwastoosmalltobeconfirmedbytheavailable
diagnostic equipment, and therefore did not require treatment.
As a result of the lack of a more appropriate diagnosis such
women might, nevertheless, be coded as having venous
thromboembolism.
Compared with non-users of combined oral contraceptives, the
relative risk of venous thromboembolism among current users
ofcombinedoralcontraceptiveswastwofoldtofourfoldhigher
forconfirmedthanunconfirmedvenousthromboembolism(table
3). The rate ratio estimates between different product groups
were less sensitive, but nevertheless decreased by about 25%
from the confirmed to the unconfirmed group (table 4).
Exposure line formation
Estimationofrateratiosthroughdifferentstepsinexposureline
formation was necessary for at least two reasons. Firstly, we
decided on the analytical strategy before the analyses started.
Secondly, the relative risk for users of specific products
compared with non-users increased slightly (not significantly)
through the different steps, indicating a successively higher
validity of exposure allocation—for example, the relative risk
estimate of oral contraceptives with levonorgestrel and 30 µg
ethinylestradiol increased from 1.9 (1.5 to 2.6) to 2.1 (1.6 to
2.8) and for those with drospirenone from 4.4 (3.7 to 5.1) to 4.7
(4.0 to 5.4) through the different exposure lines.
Owing to the high consistency in the rate ratio estimates in the
different exposure lines, it is unlikely that different rules or
other time intervals in the allocation rules would have changed
the rate ratios substantially.
Analysis of different sub-periods
Overall,therateratioestimateswerestablethroughoutthestudy
periods. The slightly lower rate ratio estimates after June 2007
compared with the previous period could be a consequence of
the media event in June 2007. Shortly after this the Danish
SocietyofObstetricsandGynaecologypublishedapressrelease
in which they stated that oral contraceptives with drospirenone
were unlikely to confer a higher risk of venous
thromboembolism than the prevailing third generation oral
contraceptives with desogestrel or gestodene, but that oral
contraceptiveswithlevonorgestrelwerelikelytoconferalower
risk. Consequently, women at an anticipated increased risk of
venousthromboembolismwererecommendedprogestogenonly
contraception or alternatively oral contraceptives with
levonorgestrel as first choice.
Therebysomewomenatananticipatedincreasedriskofvenous
thromboembolism could have been prescribed products
containing levonorgestrel, increasing the estimates for oral
contraceptiveswithlevonorgestrelanddecreasingtheestimates
forthosewithdrospirenone.However,therelativeriskestimates
for oral contraceptives with levonorgestrel and 30 µg
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RESEARCHethinylestradiol with non-users of hormonal contraception as
reference did not change: 2.3 (1.7 to 3.1) during 2001-5 and 2.4
(1.6 to 3.6) from June 2007-9. In contrast, the estimates for oral
contraceptives with drospirenone and 30 μg ethinylestradiol
decreased (non-significantly) from 4.7 (3.9 to 5.7) in 2001-5 to
4.1(3.2to5.3)during2007-9,whichmayexplainthedecreasing
trend in the rate ratio estimates after June 2007.
Recent surgery
The exclusion of 33 women with confirmed venous
thromboembolism who had major surgery within the previous
four weeks did not change the results, primarily because of the
low numbers. In addition, women undergoing surgery often
receiveanticoagulationtherapyduringtheirstay,andsomemay
have stopped using oral contraceptives in the weeks around the
surgery, circumstances for which we lacked information.
Strengths and limitations of the study
Expandingonourpreviousstudybyusingfournewyears’worth
of original data on exposure and end points confirmed our
previously published results,
18 and therefore increased the
validity of the present results. The inclusion of all Danish
non-pregnant women over a nine year period ensured a high
external validity.
The information on exposure was complete and gathered for
purposes other than a scientific analysis, eliminating the recall
bias that is common in case-control studies, and the problems
of continuous updating data on exposure in cohort studies.
Furthermore, we eliminated the problem of left censoring by
measuring use of combined oral contraceptives over a six year
period before our study started. We obtained consistent results
from sensitivity analyses on exposure line formation, different
sub-periods, and according to different user categories (for
example, starters, restarters).
Finally,wewereabletovalidatevenousthromboembolicevents
by linking individual data on diagnosis to succeeding
anticoagulation therapy. Restricting the analysis to only
confirmed events provided a quantitative assessment of the
consequence of misclassification of some diagnoses on risk
estimates.
This study does, however, have some limitations. We could not
control for family disposition and body mass index. Adiposity
is a well documented risk factor for venous thromboembolism.
It is unlikely that there should be any important preferential
prescribing of specific types of oral contraceptives to obese
women before June 2007. After that time, however, the public
recommendations to women at an anticipated increased risk of
venous thromboembolism to choose a progestogen only
contraception or oral contraceptives with levonorgestrel could
have overestimated the risk for oral contraceptives with
levonorgestrel and underestimated that for oral contraceptives
withdesogestrel,gestodene,ordrospirenone.Somecouldargue
thatobesewomenaremorelikelytochooseoralcontraceptives
with drospirenone. The empirical support for such selective
prescribing is weak, however, and does not explain the high
relative risk estimates for the other three oral contraceptives
withdesogestrel,gestodene,andcyproterone.Todate,nostudy
has shown any confounding influence from body mass index,
as adjustment for body mass index in studies with this
information did not change the rate ratio between oral
contraceptives with different progestogens.
14 17-19 Therefore,
preferential prescribing of oral contraceptives with third
generation progestogens or drospirenone to obese women is
unlikelytoexplainthedoubledriskfortheseproductscompared
with oral contraceptives containing levonorgestrel, especially
after 2006.
The same argument applies to family disposition. Although an
important risk factor, family disposition has not been found to
be an important confounder in studies over the past 10 years.
Aboutaquarterofourincludedvenousthromboembolicevents
could not be confirmed by review of the medical records. This
would underestimate the influence of combined oral
contraceptives on the risk of venous thromboembolism, as
shown by comparing the risk estimates for confirmed events in
this study with those in our primary publication,
18 whereas the
rate ratio estimates were less sensitive to the inclusion of
unconfirmed events.
The chart review confirmed a 99% positive predictive value of
a diagnosis of venous thromboembolism with subsequent
anticoagulationtherapy,andthatcrosslinkagewiththenational
registry of medicinal products provided reliable validation of
the events. However, we lost at least 10% of true events by
excluding all events that were not recorded in the registry.
Table 7⇓ summarises studies that specifically assessed the risk
of venous thromboembolism from use of oral contraceptives
with levonorgestrel, desogestrel, gestodene, or drospirenone.
We excluded those studies that did not specify the compounds
used or that lacked a reference group. Our new estimates for
specific products restricted to confirmed events of venous
thromboembolismareclosetothoseinaDutchstudy,
17whereas
the rate ratio estimates between different product groups were
slightly higher than in the Dutch study and slightly lower than
in the two new studies from the United Kingdom
20 and the
United States.
21 The UK and US studies included “idiopathic
events” only, the risk estimates of which are expected to be
slightly higher than those of studies that also include women
with some other risk factors.
The two studies that did not find any difference in risk between
oral contraceptives with drospirenone and those with
levonorgestrel were two of the three studies that did not find
any difference in risk between oral contraceptives with
desogestrel or gestodene and those with levonorgestrel.
If we anticipate that oral contraceptives with desogestrel,
gestodene, or drospirenone increase the risk of venous
thromboembolism sixfold and that those with levonorgestrel
increase the risk threefold, and that the absolute risk of venous
thromboembolism in current users of the former group is on
average 10 per 10 000 women years, then 2000 women would
need to shift from using oral contraceptives with desogestrel,
gestodene, or drospirenone to those with levonorgestrel to
prevent one event of venous thromboembolism in one year.
Conclusion
Compared with non-users of hormonal contraception, current
users of oral contraceptives with levonorgestrel had a threefold
increasedriskofvenousthromboembolismandthoseusingoral
contraceptives with desogestrel, gestodene, drospirenone, or
cyproterone a six to sevenfold increased risk.
This would give a rate ratio between the groups using oral
contraceptives with desogestrel, gestodene, drospirenone, or
cyproterone and those using oral contraceptive with
levonorgestrel of at least 2. It is unlikely that these findings
could be explained by bias or confounding.
We thank Torben Bjerregaard Larsen, expert in coagulation at Aalborg
University Hospital, and Niels Tønder, cardiologist at Hillerød University
Hospital, for their review of the 200 charts.
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RESEARCHWhat is already known on this topic
Studies have shown an increased risk of venous thrombosis (VTE) with use of combined oral contraceptives
The risk was higher with oral contraceptives containing the progestogens desogestrel and gestodene than those containing levonorgestrel
Results on the risk from oral contraceptives with drospirenone have been conflicting
What this study adds
Women using oral contraceptives with drospirenone are at similar risk of VTE to those using oral contraceptives with desogestrel,
gestodene, or cyproterone and higher than those using oral contraceptives with levonorgestrel
The risk of VTE was not reduced by using 20 µg oestrogen instead of 30 µg oestrogen in oral contraceptives with drospirenone
To prevent one event of VTE in one year about 2000 women should shift from using oral contraceptives with desogestrel, gestodene,
or drospirenone to those with levonorgestrel
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RESEARCHTables
Table 1| Characteristics of current users and non-users of combined oral contraceptives and adjusted relative risk of venous
thromboembolism according to age, calendar year, and length of education
P value
Adjusted rate ratio†
(95% CI)
Non-users Current users
Characteristics
Incidence per
10 000
exposure
years
No of
events* Women years
Incidence per
10 000
exposure
years
No of
events* Women years
Age (years):
— 1 (reference) 0.7 49 670 766 4.2 239 571 333 15-19
<0.001 1.32 (1.13 to 1.54) 2.1 74 346 614 4.8 343 713 623 20-24
<0.001 1.99 (1.66 to 2.38) 2.9 134 463 810 6.8 375 549 862 25-29
<0.001 2.91 (2.40 to 3.55) 3.2 211 667 937 8.7 375 430 272 30-34
<0.001 4.01 (3.31 to 4.87) 3.5 304 861 442 12.1 447 369 859 35-39
<0.001 5.29 (4.36 to 6.41) 4.8 467 965 951 15.2 397 261 464 40-44
<0.001 6.58 (5.43 to 7.99) 5.8 573 984 209 20.8 319 153 147 45-49
Year:
<0.001 0.71 (0.62 to 0.81) 2.8 175 625 168 7.2 241 335 482 2001
<0.001 0.76 (0.66 to 0.86) 3.3 198 601 282 7.4 251 339 078 2002
<0.001 0.70 (0.61 to 0.80) 3.0 174 579 767 7.0 238 340 575 2003
0.002 0.81 (0.72 to 0.93) 3.6 205 562 409 8.1 276 342 354 2004
0.02 0.86 (0.76 to 0.97) 4.0 217 544 028 8.1 275 341 273 2005
0.03 0.87 (0.77 to 0.99) 3.9 205 529 811 8.6 293 339 578 2006
0.82 1.01 (0.90 to 1.15) 4.7 245 516 775 9.2 311 337 072 2007
0.10 0.90 (0.79 to 1.02) 3.7 190 508 635 8.5 287 336 606 2008
— 1 (reference) 4.1 203 492 855 9.6 323 337 542 2009
Level of education:
— 1 (reference) 6.3 748 1 194 278 11.0 762 695 339 Elementary
school‡
<0.001 0.60 (0.54 to 0.67) 2.5 125 505 821 7.5 275 365 466 High school§
<0.001 0.68 (0.63 to 0.73) 4.0 518 1 295 503 11.7 673 576 803 High school and
middle education¶
<0.001 0.49 (0.44 to 0.55) 2.8 257 909 249 9.2 223 241 662 High school and
long education**
0.0005 0.78 (0.68 to 0.90) 1.6 164 1 055 878 4.8 562 1 170 290 No available
information
*Events are venous thromboembolisms.
†Age estimates adjusted for year, level of education, and use of oral contraceptives; year estimates adjusted for age, level of education, and use of combined oral
contraceptives; and education estimates adjusted for age, year, and use of combined oral contraceptives.
‡9-10 years of education.
§2-3 years of education after elementary school.
¶3-4 years of education after high school.
**5-6 years of education after high school.
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RESEARCHTable 2| Exposure time, number of events of venous thromboembolism, crude incidence per 10 000 user years, and adjusted relative risk
of venous thromboembolism in current users of different oral contraceptives and hormone releasing intrauterine device with non-users
as reference group
Adjusted relative risk† (95% CI) Crude incidence per 10 000 user years* No of events* Women years Group
1 (reference) 3.7 1812 4 960 730 Non-use
Progestogen with 50 μg ethinylestradiol:
5.66 (3.12 to 10.3) 16.1 11 6848 Norethisterone
3.54 (2.48 to 5.05) 13.1 31 23 691 Levonorgestrel
Progestogen with 30-40 μg ethinylestradiol:
1.57 (0.84 to 2.92) 3.7 10 27 355 Norethisterone
2.28 (1.85 to 2.83) 8.4 89 105 970 Phasic levonorgestrel
2.19 (1.74 to 2.75) 7.5 78 104 251 Levonorgestrel combined
2.56 (2.18 to 3.01) 6.2 165 267 664 Norgestimate
4.21 (3.63 to 4.87) 11.8 201 170 249 Desogestrel
4.23 (3.87 to 4.63) 11.0 738 668 355 Gestodene
4.47 (3.91 to 5.11) 9.3 266 286 859 Drospirenone
4.10 (3.37 to 4.99) 9.0 109 120 934 Cyproterone
Progestogen with 20 µg ethinylestradiol:
3.26 (2.88 to 3.69) 6.8 322 470 982 Desogestrel
3.50 (3.09 to 3.97) 6.8 321 472 118 Gestodene
4.84 (3.19 to 7.33) 10.0 23 23 055 Drospirenone
Progestogen only:
0.56 (0.29 to 1.07) 2.0 9 44 168 Norethisterone
0.64 (0.29 to 1.42) 2.1 6 29 187 Desogestrel
0.83 (0.63 to 1.08) 3.5 55 155 149 Levonorgestrel releasing intrauterine device
*Events are venous thromboembolisms.
†Adjusted for age, year, and level of education.
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RESEARCHTable 3| Relative risk of venous thromboembolism among current users of oral contraceptives and hormone releasing intrauterine device
according to certainty of diagnosis of venous thromboembolism, with non-users of hormonal contraception as reference group
Not recorded Anticoagulation (confirmed)
Women years Product type % confirmed
Adjusted relative risk† (95%
CI)
No of
events*
Adjusted relative risk† (95%
CI) No of events*
55.4 1 (reference) 808 1 (reference) 1004 4 960 730 Non-use
Progestogen with 50 µg
ethinylestradiol:
63.6 5.10 (1.90 to 13.7) 4 6.24 (2.95 to 13.2) 7 6848 Norethisterone
71.0 2.34 (1.21 to 4.52) 9 4.49 (2.94 to 6.85) 22 23 691 Levonorgestrel
Progestogen with 30-40 µg
ethinylestradiol:
80.0 0.73 (0.18 to 2.91) 2 2.24 (1.12 to 4.51) 8 27 355 Norethisterone
74.2 1.31 (0.86 to 1.98) 23 3.09 (2.41 to 3.97) 66 105 970 Levonorgestrel phasic
73.1 1.30 (0.84 to 2.00) 21 2.92 (2.23 to 3.81) 57 104 251 Levonorgestrel combined
72.1 1.44 (1.07 to 1.95) 46 3.52 (2.90 to 4.27) 119 267 664 Norgestimate
83.6 1.43 (1.01 to 2.04) 33 6.61 (5.60 to 7.80) 168 170 249 Desogestrel
77.9 1.92 (1.61 to 2.28) 163 6.24 (5.61 to 6.95) 575 668 355 Gestodene
73.7 2.32 (1.80 to 2.98) 70 6.37 (5.43 to 7.47) 196 286 859 Drospirenone
80.7 1.58 (1.02 to 2.44) 21 6.35 (5.09 to7.93) 88 120 934 Cyproterone
Progestogen with 20 µg
ethinylestradiol:
76.4 1.52 (1.19 to 1.94) 76 4.81 (4.15 to 5.56) 246 470 982 Desogestrel
74.8 1.72 (1.36 to 2.19) 81 5.07 (4.37 to 5.88) 240 472 118 Gestodene
69.6 2.58 (1.22 to 5.46) 7 6.95 (4.21 to 11.5) 16 23 055 Drospirenone
Progestogen only:
66.7 0.41 (0.13 to 1.28) 3 0.68 (0.30 to 1.51) 6 44 168 Norethisterone
50.0 0.63 (0.20 to 1.97) 3 0.61 (0.20 to 1.90) 3 29 187 Desogestrel
47.3 0.95 (0.65 to 1.38) 29 0.72 (0.49 to 1.06) 26 155 149 Levonorgestrel releasing
intrauterine device
*Events are venous thromboembolisms.
†Adjusted for age, calendar year, and level of education.
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RESEARCHTable 4| Rate ratios of venous thromboembolism between users of combined oral contraceptives with different progestogens according
to certainty of diagnosis of venous thromboembolism
P value
Rate ratio†
No of events* Comparison groups Fully adjusted‡ (95% CI) Partially adjusted
Confirmed events
Drospirenone + 30 μg EE versus:
<0.001 2.12 (1.68 to 2.66) 2.03 196 v 123 Levonorgestrel + 30-40 μg EE (all)
<0.001 2.18 (1.62 to 2.94) 2.08 196 v 57 Levonorgestrel + 30 μg EE (without phasic preparations)
0.9248 1.01 (0.86 to 1.18) 0.98 196 v 743 Third generation progestogens§
<0.001 2.20 (1.74 to 2.77) 2.18 168 v 123 Desogestrel + 30 μg EE v levonorgestrel + 30-40 μg EE
<0.001 2.07 (1.70 to 2.52) 2.04 575 v 123 Gestodene + 30 μg EE v levonorgestrel + 30-40 μg EE
Non-confirmed events
Drospirenone + 30 μg EE versus:
0.0032 1.78 (1.21 to 2.60) 1.71 70 v 44 Levonorgestrel + 30-40 μg EE
0.0213 1.78 (1.09 to 2.91) 1.70 70 v 21 Levonorgestrel + 30 μg EE (without phasic preparations)
0.0840 1.27 (0.97 to 1.68) 1.25 70 v 196 Third generation progestogens§
0.6764 1.10 (0.70 to 1.73) 1.10 33 v 44 Desogestrel + 30 μg EE v levonorgestrel + 30-40 μg EE
0.0236 1.47 (1.05 to 2.06) 1.45 163 v 44 Gestodene + 30 μg EE v levonorgestrel + 30-40 μg EE
EE=ethinylestradiol.
*Events are venous thromboembolisms.
†Adjusted for age and calendar year.
‡Adjusted for age, calendar year, and level of education.
§Desogestrel or gestodene.
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RESEARCHTable 5| Rate ratio of confirmed venous thromboembolism between different combined oral contraceptives with adjustment for length of
use
P value Adjusted rate ratio† (95% CI) No of events* Women years Product group
Progestogen with 30-40 μg ethinylestradiol:
0.47 0.76 (0.36 to 1.60) 8 27 355 Norethisterone
0.71 1.07 (0.75 to 1.52) 66 105 970 Levonorgestrel phasic
— 1 (reference) 57 104 251 Levonorgestrel combined
0.30 1.18 (0.86 to 1.62) 119 267 664 Norgestimate
<0.001 2.24 (1.65 to 3.02) 168 170 249 Desogestrel
<0.001 2.12 (1.61 to 2.78) 575 668 355 Gestodene
<0.001 2.09 (1.55 to 2.82) 196 286 859 Drospirenone
<0.001 2.11 (1.51 to 2.95) 88 120 934 Cyproterone
Progestogen with 20 μg ethinylestradiol:
0.0015 1.60 (1.20 to 2.14) 246 470 982 Desogestrel
0.0004 1.70 (1.27 to 2.27) 240 472 118 Gestodene
0.005 2.22 (1.27 to 3.89) 16 23 055 Drospirenone
*Events are venous thromboembolisms.
†Adjusted for age, calendar year, level of education, and length of use.
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RESEARCHTable 6| Relative risk of venous thromboembolism in current users of combined oral contraceptives according to length of use and with
non-users of hormonal contraception as reference
Adjusted relative risk† (95% CI)
No of events* Women years Product type >4 years >1-4 years 3-12 months <3 months
1 (reference) 1 (reference) 1 (reference) 1 (reference) 1812 4 960 730 Non-use
Progestogen with 30-40 μg ethinylestradiol:
1.88 (1.45 to 2.43) 2.12 (1.61 to 2.80) 2.54 (1.80 to 3.59) 4.07 (2.70 to 6.15) 167 210 221 Levonorgestel (all)
1.82 (1.27 to 2.59) 2.47 (1.91 to 3.20) 2.98 (2.22 to 4.00) 3.81 (2.60 to 5.58) 165 267 664 Norgestimate
4.64 (3.64 to 5.92) 3.77 (2.95 to 4.81) 4.20 (3.11 to 5.67) 4.59 (3.01 to 7.00) 201 170 249 Desogestrel
3.94 (3.43 to 4.54) 4.12 (3.61 to 4.70) 4.65 (3.96 to 5.45) 4.83 (3.85 to 6.05) 738 668 355 Gestodene
4.34 (3.10 to 6.08) 3.38 (2.69 to 4.24) 5.95 (4.88 to 7.24) 4.70 (3.45 to 6.40) 266 286 859 Drospirenone
2.43 (1.41 to 4.19) 4.90 (3.70 to 6.49) 4.21 (2.95 to 6.01) 4.23 (2.50 to 7.17) 109 120 934 Cyproterone
Progestogen with 20 μg ethinylestradiol:
3.09 (2.42 to 3.96) 3.49 (2.91 to 4.17) 3.18 (2.55 to 3.98) 3.18 (2.31 to 4.38) 322 470 982 Desogestrel
2.65 (2.00 to 3.51) 3.38 (2.81 to 4.06) 4.51 (3.69 to 5.52) 3.46 (2.49 to 4.81) 321 472 118 Gestodene
— 2.58 (0.96 to 6.89) 7.25 (4.19 to 12.56) 6.16 (2.76 to 13.77) 23 23 055 Drospirenone
*Events are venous thromboembolisms.
†Adjusted for age, calendar year, and level of education.
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RESEARCHTable 7| Relative risk of venous thromboembolism in current users of different combined oral contraceptives according to study. Non-users
of hormonal contraception as reference group unless specified otherwise
Relative risk (95% CI)
No of events* Sampling period Study COC with drospirenone COC with third generation progestogens† COC with levonorgestrel
NA 8.7 (3.9 to 19.3) 3.8 (1.7 to 8.4) 126 1988-92 Bloemenkamp
1
NA 7.4 (4.2 to 12.9) 3.6 (2.5 to 5.1) 433 1989-93 WHO
4
NA 1.8 (1.0 to 3.2) 1 (Reference) 80 1991-4 Jick
2
NA 6.7 (3.4 to 13) 3.7 (2.2 to 6.2) 471 1991-5 Spitzer
5
NA 5.0‡ (3.7 to 6.5) 3.1‡ (2.1 to 4.5) 85 1991-5 Farmer
6
NA 2.3 (1.5 to 3.5) 2.9 (1.9 to 4.2) 502 1993-5 Lewis
8
NA 1.4 (0.7 to 2.8) 1 (Reference) 99 1992-7 Todd
9
NA 5.6 (NA) 3.7 (1.9 to 7.2) 185 1994-8 Bloemenkamp
7
NA 4.0 (3.2 to 4.9) 2.9 (2.2 to 3.8) 987 1994-8 Lidegaard
13
1.0 (0.6 to 1.8) 1.3 (NS) 1 (Reference) 118 2000-4 Dinger
14
6.3 (2.9 to 13.7) 7.3 (5.3 to 10.0) 3.6 (2.9 to 4.6) 1524 1999-2004 Vlieg
17
4.0 (3.3 to 4.9) 3.6 (3.3 to 3.8) 2.0 (1.8 to 2.3) 4213 1995-2005 Lidegaard
18
1.0 (0.6 to 1.8) NA 1 (Reference) 680 2002-8 Dinger
19
2.7 (1.5 to 4.7) NA 1 (Reference) 61 2002-9 Parkin
20
2.8 (2.1 to 3.8) NA 1 (Reference) 186 2002-8 Jick
21
Present study:
4.5 (3.9 to 5.1) 4.2 (3.6 to 4.9) 2.2 (1.7 to 2.8) 4246 2001-9 All reported events*
6.3 (5.4 to 7.5) 6.8 (5.7 to 8.1) 2.9 (2.2 to 3.8) 2707 2001-9 Confirmed events only*
COC=combined oral contraceptives; NA=not available; NS=non-significant.
*Events are venous thromboembolisms.
†Desogestrel or gestodene.
‡Absolute risk per 10 000 women years.
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RESEARCH